We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Next-Generation Occluder Reduces Stroke Risk

By HospiMedica International staff writers
Posted on 05 Feb 2013
A novel occluder closes the left atrial appendage (LAA) in patients diagnosed with nonvalvular atrial fibrillation (AF), potentially reducing the risk of stroke.

The Amplatzer Amulet LAA occluder is a self-expanding, braided Nitinol mesh that blocks the LAA at its aperture, minimizing the opportunity for blood clots to form or migrate into the bloodstream. More...
The next-generation device is built with a longer lobe and waist than previous versions to allow for easier placement, and an end screw that is set flush with the occluding disc, creating a smooth surface within the left atrium. The large disc diameter offers increased orifice coverage. The device is preloaded into the delivery catheter, which simplifies device preparation and ultimately streamlines the entire procedure for the physician.

The Amplatzer Amulet LAA device is a product of St. Jude Medical (SJM; St. Paul, MN, USA) and is offered in eight sizes to accommodate varying anatomies.

“Feedback from implanting physicians who have used our first-generation product has been instrumental to improving an already successful device,” said Frank J. Callaghan, president of the cardiovascular and ablation technologies division at SJM. “We are pleased to offer a next-generation LAA occluder that addresses a wider range of patient anatomies, is easier to implant, and has the potential to further reduce the incidence of stroke in AF patients.”

The LAA is a tube-shaped appendage connected to the left atrium that can potentially hold static blood during an episode of AF, increasing the likelihood of clot formation; research shows that in AF patients, approximately 90% of all cardiac blood clots form in the LAA. If a clot forms in the LAA and is then released into the heart, it may enter blood circulation, travel to the brain, block a vessel, and cause an ischemic stroke.

Related Links:
St. Jude Medical


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
New
Patient Monitoring System
AlarmSense
New
Medical-Grade Display
HL2316SHTB
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Health IT

view channel
Photo courtesy of Adobe Stock

Automated System Classifies and Tracks Cardiogenic Shock Across Hospital Settings

Cardiogenic shock remains a difficult, time-sensitive emergency, with delayed identification driving poor outcomes and persistently high mortality. Many cases go undocumented even at advanced stages, hindering... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.